Immuno & Gene Therapy Committee

 Charter

 The Immuno & Gene Therapy Committee strives to:

  • Assist in the planning of the annual meeting scientific program and the review of submitted abstracts in the dendritic cell and immunotherapy category.
  • Review the status of the immuno & gene therapy field and compile a list of major scientific issues that must be addressed to advance or enable cellular therapies utilizing immunotherapy and gene therapy.
  • Publish position papers and engage in scientific discourse as necessary to advance the field.

Projects and Objectives

  •  Contribute to the ISCT Annual Meeting program.


Committee Members:



Kenneth Micklethwaite, MD
Co-Chair (Jan 2018 – Dec 2018) 
The Westmead Institute for Medical Research
Sydney, Australia

Patrick Hanley, PhD
Co-Chair (Jan 2018 – Dec 2018)
Children's National Medical Center
Washington, DC, United States

 

 

Lisa Butterfield, PhD
University of Pittsburgh
Pittsburgh, PA, United States
Bruce Levine, PhD
University of Pennsylvania
Philadelphia, PA, United States
   
Michaela Sharpe, PhD
Cell and Gene Therapy Catapult
London, United Kingdom
Mitchell Cairo, MD
New York Medical College
New York, NY, United States
   
Sandeep Soni, MD 
Stanford University
Stanford, CA, United States
Wei Dong Han, MD
Chinese PLA General Hospital
Beijing, China
   
David Gottlieb, MBBS, FRACP, FRCPA, MD
Westmead Hospital
Sydney, NSW, Australia
Donald Kohn, MD
University of California
Los Angeles, CA, United States
   
Mark Lowdell, PhD, FRCPath, FBS
University College London
London, United Kingdom
Sung-Yun Pai, MD
Boston Children's Hospital
Boston, MA, United States
   

 

© 2018 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered service marks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.